[go: up one dir, main page]

AU2002356369A1 - Xanthine derivatives as muscarinic receptor antagonists - Google Patents

Xanthine derivatives as muscarinic receptor antagonists

Info

Publication number
AU2002356369A1
AU2002356369A1 AU2002356369A AU2002356369A AU2002356369A1 AU 2002356369 A1 AU2002356369 A1 AU 2002356369A1 AU 2002356369 A AU2002356369 A AU 2002356369A AU 2002356369 A AU2002356369 A AU 2002356369A AU 2002356369 A1 AU2002356369 A1 AU 2002356369A1
Authority
AU
Australia
Prior art keywords
receptor antagonists
muscarinic receptor
xanthine derivatives
xanthine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002356369A
Other languages
English (en)
Inventor
Jang Bahadur Gupta
Anita Mehta
Sanjay Kumar Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of AU2002356369A1 publication Critical patent/AU2002356369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002356369A 2002-12-23 2002-12-23 Xanthine derivatives as muscarinic receptor antagonists Abandoned AU2002356369A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/005589 WO2004056810A1 (fr) 2002-12-23 2002-12-23 Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques

Publications (1)

Publication Number Publication Date
AU2002356369A1 true AU2002356369A1 (en) 2004-07-14

Family

ID=32676694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002356369A Abandoned AU2002356369A1 (en) 2002-12-23 2002-12-23 Xanthine derivatives as muscarinic receptor antagonists

Country Status (4)

Country Link
EP (1) EP1590345A1 (fr)
AU (1) AU2002356369A1 (fr)
CA (1) CA2511726A1 (fr)
WO (1) WO2004056810A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419236T1 (de) 2002-07-08 2009-01-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
EP1626957A1 (fr) 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Derives azabicyclo utiles comme antagonistes du recepteur muscarinique
DE602004018844D1 (de) * 2004-06-16 2009-02-12 Ranbaxy Lab Ltd Als antagonisten des muscarinrezeptors geeignete xanthinderivate
EP1934184A1 (fr) 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. Dérivés de 3 -azabicyclooctane en tant qu antagonistes de récepteurs muscariniques
WO2007110782A1 (fr) 2005-12-30 2007-10-04 Ranbaxy Laboratories Limited Antagonistes des récepteurs muscariniques
BRPI0620844A2 (pt) 2005-12-30 2011-11-29 Ranbaxy Lab Ltd compostos antagonistas dos receptores muscarìnicos, seus métodos de preparação, composições farmacêuticas compreendendo os mesmos, usos dos referidos compostos na preparação de medicamentos
US8202891B2 (en) 2007-04-24 2012-06-19 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
CA3142351A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8721978A0 (it) * 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Also Published As

Publication number Publication date
CA2511726A1 (fr) 2004-07-08
EP1590345A1 (fr) 2005-11-02
WO2004056810A1 (fr) 2004-07-08

Similar Documents

Publication Publication Date Title
AP1828A (en) Muscarinic Acetycholine receptor antagonists
AU2003241836A1 (en) Lpa receptor antagonists
AU2003261392A1 (en) M3muscarinic acetylcholine receptor antagonists
IL165863A0 (en) Indole derivatives useful as histamine H3 antagonists
ZA200408670B (en) Trizole derivatives as tachykinin receptor antagonists.
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2003215549A1 (en) Mercaptoimidazoles as ccr2 receptor antagonists
PL1636206T3 (pl) Pochodne imidazolu jako antagoniści receptorów glutaminianu
PL372463A1 (en) Thiazole derivatives as npy receptor antagonists
AU2002356369A1 (en) Xanthine derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2003205964A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2005234596A8 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
AU2003214520A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003300904A1 (en) Antagonists for human prolactin
AU2003223010A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003297408A1 (en) Thiazole compounds as integrin receptor antagonists derivatives
AU2003267802A1 (en) Quaternary ammonium compounds as muscarinic receptor antagonists
AU2003286316A1 (en) 5-aminophenanthridine derivatives as npy-5 antagonists
AU2003297409A1 (en) Pyrazole compounds as integrin receptor antagonists derivatives
AU2002334103A1 (en) Azabicyclic spiroether derivatives as receptor antagonists
HK1092357A (en) Muscarinic acetycholine receptor antagonists
AU2003261206A1 (en) Xanthine derivatives having adenosine a1-receptor antagonist properties
HK1071520A (en) Azetidine derivatives as ccr-3 receptor antagonists
HK1106509A (en) Pyrrolidine derivatives as muscarinic receptor antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase